The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha-isoform specific PI3K inhibitor, (b) an MDM2 inhibitor, and optionally (c) a BCL-2 inhibitor combined preparations and pharmaceutical compositions thereof the uses of such combination in the treatment or prevention of cancer and methods of treating or preventing cancer a subject in need thereof comprising administering a therapeutically effective amount of such combination.
